Improving Quality Control for CAR T Cell Therapies

CAR T cell therapy has revolutionized cancer treatment, providing a targeted approach that harnesses the power of the immune system. However, ensuring the safety and efficacy of CAR T cell therapies requires a new approach to quality control. From the development of the first CAR T cell therapy to the identification of the right target and the challenges of manufacturing, researchers are focused on addressing these critical issues. By using droplet-digital PCR (DD-PCR) technology, scientists can accurately quantify copy number variation, detect replication-competent viruses, and monitor CAR T cell persistence in patients' blood, ultimately enhancing the development and activity of CAR T cell therapies.